Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totaling 27,047 shares, a decline of 96.4% from the April 30th total of 751,721 shares. Approximately 0.6% of the company’s shares are sold short. Based on an average daily trading volume, of 106,890 shares, the days-to-cover ratio is presently 0.3 days.
Sonoma Pharmaceuticals Stock Performance
Shares of NASDAQ:SNOA traded up $0.03 on Thursday, hitting $1.11. 85,897 shares of the company’s stock were exchanged, compared to its average volume of 118,819. The company has a market capitalization of $5.29 million, a PE ratio of -0.54 and a beta of 1.28. Sonoma Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $6.92. The firm’s 50-day moving average is $1.77 and its 200 day moving average is $2.73.
Institutional Trading of Sonoma Pharmaceuticals
A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. acquired a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned about 0.66% of Sonoma Pharmaceuticals as of its most recent SEC filing. 1.95% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.
At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.
Featured Articles
- Five stocks we like better than Sonoma Pharmaceuticals
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
- IREN Is Flipping the Switch from Bitcoin to AI
- This Quantum Computing Stock May Be Closer to a Breakout Than You Think
- RTX Is Set to Revolutionize Munitions Manufacturing
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
